Da 
https://www.bloomberg.com/news/articles/2023-07-21/meet-your-new-ai-chatbot-co-worker

For Chinese who do almost everything on their smartphones, seeing a
doctor online doesn’t sound like a novel idea. But the way technology
is headed in the country, they’ll soon wonder if they’re talking to a
real doctor — or one that’s powered by so-called generative AI tools
similar to ChatGPT.

Chinese online healthcare provider Medlinker in May unveiled an AI
doctor dubbed MedGPT, claiming it’s capable of diagnosing some of the
most common diseases with the same degree of accuracy and consistency
of a human doctor.

In fact, AI has already been widely applied in online consultations
offered by some of China’s leading Internet healthcare services — but
it largely serves an auxiliary role. Patients wanting to chat with a
doctor online sometimes find themselves talking to chatbots first,
which collect basic information from patients and redirect them to the
suitable human specialist.

What sets MedGPT apart, according to Medlinker, is that it could
handle the entire process on its own, from diagnosis to prescribing
tests and medication — replacing human doctors.

Medlinker crammed tens of billions of medical records and academic
journals into MedGPT, with the chatbot powered by ChatGPT-style
services developed by domestic and foreign firms. A team of over 100
human doctors then trained the chatbot to assess a patient and take
appropriate actions, such as ordering medical tests, prescribing
medicines or offering dietary guidance.

MedGPT is a very inquisitive doctor: The chatbot engages patients in
multiple rounds of questioning to get as much information as possible
before arriving at a conclusion. But how does it stack up against
human counterparts?

Attendants photograph the stage as Sam Altman, chief executive officer
of OpenAI, speaks during an event in Seoul last month.  Photographer:
SeongJoon Cho/Bloomberg

A month after MedGPT’s unveiling, Medlinker ran a trial pitting it
against 10 senior human specialists, consulting more than 100 patients
with issues from cardiovascular problems to kidney disease.

MedGPT and the physicians got similar scores, and a judging panel of
seven doctors credited the chatbot for being comprehensive in its
questioning and refraining from giving diagnoses too early. Still,
they also noted shortcomings: Some of the tests MedGPT ordered were
repetitive, and recommended treatments could be excessive.

“MedGPT still has lots of problems, but I think the strides it has
made is a milestone,” said Ren Jingyi, a cardiologist at a top Beijing
hospital, one of the seven experts — and only one of two to rate the
bot higher than its human counterparts.

MedGPT isn’t yet in commercial use, pending government approval — and
guidelines for the real-world application of such generative AI tools
for healthcare. The company said it is looking for partnership with
companies and medical institutions to improve the AI doctor’s
accuracy, train it to diagnose more diseases and run a bigger trial
later this year. It also hopes to work with medical experts to
establish standards for AI-based healthcare services.

It could be a matter of when, rather than if, AI doctors will be able
to independently treat humans. But whether they’ll replace some human
doctors or be support tools remains to be seen.
_______________________________________________
nexa mailing list
nexa@server-nexa.polito.it
https://server-nexa.polito.it/cgi-bin/mailman/listinfo/nexa

Reply via email to